Related Experiment Video

Updated: May 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy

Masato Kishida1, Kazunori Ishige, Tomohisa Horibe

  • 1Department of Biomedical Chemistry, Graduate school of Medicine, The University of Tokyo, Tokyo 113-0033.

Oncology Letters
|June 29, 2012
PubMed

Insights

The orexin 2 receptor (OX2R) is present in gallbladder, head and neck, and glioblastoma cancers. This OX2R receptor shows potential as a target for novel antibody-drug conjugate (ADC) cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Targeting tumor-specific receptors is a key strategy for developing effective cytotoxic cancer therapies.
  • The orexin 2 receptor (OX2R) has been suggested as a potential cancer target due to its reported expression in some tumors but not normal cells.

Purpose of the Study:

  • To comprehensively assess the expression levels and localization of the orexin 2 receptor (OX2R) across diverse cancer cell lines and clinical samples.
  • To evaluate OX2R as a potential therapeutic target for antibody-drug conjugate (ADC) or immunotoxin-based cancer treatments.

Main Methods:

  • Development of a specific polyclonal antibody for OX2R detection.
  • Analysis of OX2R expression in 36 cancer cell lines using reverse transcription polymerase chain reaction (RT-PCR) and Western blot.
  • Immunohistochemical analysis of OX2R expression in 221 clinical tissue array samples.

Main Results:

  • OX2R expression was detected in cell lines from gallbladder, squamous cell carcinoma of the head and neck (SCCHN), and glioblastoma.
  • Immunohistochemistry revealed OX2R expression in 31.2% (69/221) of clinical samples, primarily localized to the cell membrane.
  • The study identified specific cancer types exhibiting OX2R expression, indicating potential therapeutic windows.

Conclusions:

  • OX2R is expressed in several cancer cell types and clinical specimens, confirming its presence on cancer cell membranes.
  • OX2R represents a promising molecular target for developing targeted cancer therapies like immunotoxins and ADCs.
  • Further large-scale clinical studies are warranted to validate the statistical significance and clinical relevance of OX2R expression in various tumor types.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: